[go: up one dir, main page]

WO2000023568A3 - Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells - Google Patents

Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells Download PDF

Info

Publication number
WO2000023568A3
WO2000023568A3 PCT/US1999/015734 US9915734W WO0023568A3 WO 2000023568 A3 WO2000023568 A3 WO 2000023568A3 US 9915734 W US9915734 W US 9915734W WO 0023568 A3 WO0023568 A3 WO 0023568A3
Authority
WO
WIPO (PCT)
Prior art keywords
overproduction
compositions
cells
methods
oxygen species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015734
Other languages
French (fr)
Other versions
WO2000023568A2 (en
Inventor
Michael Brownlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2000023568A2 publication Critical patent/WO2000023568A2/en
Publication of WO2000023568A3 publication Critical patent/WO2000023568A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The subject invention provides means of identifying agents identified as capable of reducing levels of ROS or ROS level correlated indicators such as levels of LPs, AGEs, NFλB, PKC, or aldose reductase activation in insulin-independent cells grown under high glucose conditions.
PCT/US1999/015734 1998-10-06 1999-07-12 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells Ceased WO2000023568A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16718298A 1998-10-06 1998-10-06
US09/167,182 1998-10-06
US30568899A 1999-05-04 1999-05-04
US09/305,688 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000023568A2 WO2000023568A2 (en) 2000-04-27
WO2000023568A3 true WO2000023568A3 (en) 2000-09-14

Family

ID=26862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015734 Ceased WO2000023568A2 (en) 1998-10-06 1999-07-12 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
PCT/US1999/023457 Ceased WO2000019993A2 (en) 1998-10-06 1999-10-06 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023457 Ceased WO2000019993A2 (en) 1998-10-06 1999-10-06 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells

Country Status (2)

Country Link
AU (1) AU6421899A (en)
WO (2) WO2000023568A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
CN1156478C (en) 1999-01-25 2004-07-07 国家犹太医疗及研究中心 Substituted porphyrins
FR2806911B1 (en) * 2000-03-28 2003-01-10 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
JP2005508864A (en) 2001-06-01 2005-04-07 ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター Oxidant scavengers for the treatment of diabetes or for use in transplantation or for induction of immune tolerance
ATE443158T1 (en) * 2001-12-13 2009-10-15 Univ Virginia VECTOR-MEDIATED ORGANELLE TRANSFECTION
PL210225B1 (en) 2001-12-14 2011-12-30 Alcon Superoxide dismutase mimics for the treatment of ocular disorders and diseases
MXPA05005937A (en) * 2002-12-06 2005-08-18 Alcon Inc Histone deacetylase inhibitors for treating degenerative diseases of the eye.
EP2418281B1 (en) 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
JP2007513948A (en) 2003-12-11 2007-05-31 アルコン，インコーポレイテッド Superoxide dismutase mimics for the treatment of optic nerve damage and retinal damage
WO2005060986A1 (en) * 2003-12-12 2005-07-07 Albert Einstein College Of Medicine Of Yeshiva University Glp-1 (9-36) methods and compositions
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2008044138A1 (en) * 2006-10-12 2008-04-17 Syddansk Universitet Optical nanosensor for detection of reactive oxygen species
PL2275524T3 (en) 2008-02-29 2012-03-30 Buck Chemie Gmbh Adhesive agent for application on a sanitary object
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
AU2009280042B2 (en) 2008-05-23 2015-06-04 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US9572816B2 (en) 2012-10-25 2017-02-21 Technion Research And Development Foundation Ltd. Method of treatment of disease
EP3538115A4 (en) * 2016-11-14 2020-04-22 Memorial Sloan Kettering Cancer Center SCHWANN CELLS DERIVED FROM STEM CELLS
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for fat graft retention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (en) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd Preventive and therapeutic agent for diabetic complication
WO1998027426A1 (en) * 1996-12-17 1998-06-25 University Of Aberdeen Channel mediating substrates
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
JPH11507621A (en) * 1995-06-07 1999-07-06 モンサント カンパニー Process for producing substituted polyaza macrocycles
DE69813898T2 (en) * 1997-11-03 2004-03-11 Duke University SUBSTITUTED PORPHYRINES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (en) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd Preventive and therapeutic agent for diabetic complication
WO1998027426A1 (en) * 1996-12-17 1998-06-25 University Of Aberdeen Channel mediating substrates
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CURCIO, F. AND CERIELLO, A.: "Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, vol. 28A, no. 11-12, November 1992 (1992-11-01) - December 1992 (1992-12-01), pages 787 - 790, XP000879178 *
DATABASE WPI Section Ch Week 199308, Derwent World Patents Index; Class B05, AN 1993-061598[08], XP002131312, "New drug for preventing and treating diabetic complications comprises 1,4-benzoquinone or its hydroquinone form; treats nephropathy, neuropathy, arteriosclerosis etc." *
ELLIS, E.A. ET AL.: "Increased NADH oxidase activity in the retina of the BBZ/WOR diabetic rat", FREE RADICAL BIOLOGY AND MEDICINE, vol. 24, no. 1, 1 January 1998 (1998-01-01), pages 111 - 120, XP000879172 *
GIARDINO, I. ET AL.: "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells.", JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 6, March 1996 (1996-03-01), pages 1422 - 1428, XP000879169 *
KING, G.L. AND BROWNLE, M.: "The cellualr and molecular mechanisms of diabetic complications", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 25, no. 2, June 1996 (1996-06-01), pages 255 - 270, XP000878790 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Also Published As

Publication number Publication date
WO2000023568A2 (en) 2000-04-27
WO2000019993A3 (en) 2001-03-01
WO2000019993A2 (en) 2000-04-13
AU6421899A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
WO2000023568A3 (en) Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO1999051142A3 (en) Non-invasive tissue glucose level monitoring
WO2003069308A3 (en) Method of determining an analyte concentration in a sample from an absorption spectrum
WO2000028090A3 (en) Diagnostic assay for cancer
CA2222680A1 (en) Endoparasiticidal agents
AU6362100A (en) Derivatized polyurethane compositions and methods of making
AU2889201A (en) Automatic water toxicity measuring apparatus
WO2005000229A3 (en) Compositions and methods for modulating s-nitrosoglutathione reductase
TR200002113T2 (en) The use of lysophosphatidylethanolamine (18: 1) and lysophosphatidylinositol to delay aging and increase fruit ripening.
WO2002008461A3 (en) A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
MXPA01011182A (en) Methods, compositions and kits for biological indicator of sterilization.
WO2004094675A3 (en) Compositions and methods for determining the presence of sars coronavirus in a sample
WO2001096604A3 (en) Assay for genetic polymorphisms using scattered light detectable labels
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
HK1039965A1 (en) Methods and kits for detection of cryptosporidium parvum
WO2003066817A3 (en) Compositions and methods for rolling circle amplification
AU2001266274A1 (en) Assay techniques based on growth stage dependent expression inc. elegans
WO2002010752A3 (en) Sensor chips with multi-layers of polysiloxane
AU1740500A (en) Thyroid peroxidase autoantibody assay compositions, method and kit
WO2004009843A3 (en) Detection of microorganisms
AU2001269730A1 (en) Low carbohydrate compositions, kits thereof, and methods of use
AU2001287818A1 (en) Method and installation for opening eggs
GB9923858D0 (en) Antimicrobial compositions
AU3315200A (en) 1,5-anhydro-d-fructose substituted with a hydrophobic group for use as anti-oxidant and/or emulsifier

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase